Announced Tue, 23 Sept · 15:27 IST

Outcome of the 36th Annual General Meeting of the Company held on September 23, 2025, i.e., Today at 11:30 a.m. through VC/OAVM.

Related Party TransactionsBoard & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Pharmaids Pharmaceuticals held its 36th AGM on September 23, 2025, via video conferencing from 11:30 a.m. to 12:21 p.m., with 88 members present. The Chairman, Dr. Shankarappa Nagaraja Vinaya Babu, could not attend due to a medical emergency, and Independent Director Mr. Pattamadai Natarajasarma Vijay was elected to chair the meeting. Six resolutions were considered, including adoption of audited standalone and consolidated financial statements for FY25, reappointment of a retiring director, continuation of an independent director beyond age 75, appointment of a new secretarial auditor, and approval of material related party transactions for the company and its subsidiaries. E-voting results were to be submitted to BSE within the stipulated timeline, and both the Statutory Auditor's and Secretarial Auditor's reports contained no qualifications.

Likely market impact

This is a routine AGM outcome filing — no business-altering decisions were announced. Shareholders should watch for the e-voting results, which will confirm whether all resolutions (including the material related party transactions) were approved. The absence of audit qualifications is a positive governance signal, while the medical emergency involving the Chairman is worth noting for leadership continuity.